A Phase I Study to Investigate the Safety, Tolerability and Pharmacokinetics of Napabucasin Combined with Sorafenib in Japanese Patients with Unresectable Hepatocellular Carcinoma
Takuji Okusaka; Manabu Morimoto; Yuichiro Eguchi; Shinichiro Nakamura; Shuichi Iino; Rie Kageyama · 2023 · Drugs in R&D
WASTE classifies this as Negative / Null Result Report · AI classification, approximate
The study found no significant effect — useful as a negative control or null benchmark for your own design.
Abstract (excerpt)
BACKGROUND AND OBJECTIVE: For patients with advanced hepatocellular carcinoma (HCC), the standard of care for many years has been sorafenib. Preliminary data have suggested that the combination of the NAD(P)H:quinone oxidoreductase 1…
Excerpt shown for reference under fair use — read the full paper at the publisher.
About to run something similar?
Run an AI Precheck on your own design to catch failure modes like this one before you spend the time. Your first desk check is free.
Related failures
Solvent‐Free Ball‐Milling Biginelli Reaction by Subcomponent Synthesis
Negative / Null Result ReportNovel psychoactive substance consumption is more represented in bipolar disorder than in psychotic disorders: A multicenter‐observational study
Negative / Null Result ReportAcute liver failure
Negative / Null Result ReportA Lack of Significant Effect of POR*28 Allelic Variant on Tacrolimus Exposure in Kidney Transplant Recipients
Negative / Null Result ReportMenthol concentration in topical cold gel does not have significant effect on skin cooling
Negative / Null Result ReportDevelopment of a digital twin of a tablet that mimics a real solid dosage form: Differences in the dissolution profile in conventional mini-USP II and a biorelevant colon model
WASTE indexes this work — it does not host or republish it. Failure-type classification is automated and approximate.
Metadata source: OpenAlex · DOI 10.1007/s40268-023-00416-8